{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:38:46Z","timestamp":1783996726287,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007015","name":"The University of Wisconsin\u2013Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"School of Pharmacy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dalbavancin is a long-acting lipoglycopeptide antibiotic that is increasingly utilized for infections that require prolonged treatment durations despite the lack of Food and Drug Administration approval for these indications. There is no consensus regarding optimal dosing of dalbavancin for these infections and no available pharmacokinetic studies to identify optimal dosing for long-term use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An in silico pharmacokinetic simulation was performed to assess the predicted dalbavancin concentration resulting from commonly utilized dosing regimens, in addition to modified regimens. The primary endpoint evaluated was days of median 24-hour free area under the curve over the minimum inhibitory concentration (AUC\/MIC) &amp;gt;27.1, the established PK target.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A dosing regimen of 1500 mg on day 0 and day 7 resulted in median AUC\/breakpoint value above the target for 57 days (lower 95% confidence interval [CI], 37 days). A modified regimen of 1500 mg on day 0 and day 21 resulted in an additional 11 days of median AUC\/breakpoint target attainment. The other standard dosing regimen modeled was 1000 mg on day 0, then 500 mg weekly for 5 doses. This regimen achieved the AUC\/breakpoint target for 76 days (lower 95% CI, 59 days). This regimen was modified to 1000 mg on day 0, then 500 mg on days 14 and 28, which shortened the median effective treatment duration by 14 days but required 3 fewer doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These simulated results, when combined with the favorable observational data, support the use of commonly reported dalbavancin regimens for prolonged therapy durations. In addition, these pharmacokinetic\/pharmacodynamic data support extending the dosing interval beyond the frequently reported weekly regimens, which should be investigated further with a clinical trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae315","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:52:30Z","timestamp":1717581150000},"source":"Crossref","is-referenced-by-count":13,"title":["Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6749-4170","authenticated-orcid":false,"given":"Cecilia F","family":"Volk","sequence":"first","affiliation":[{"name":"Pharmacy Practice and Translational Research Division, School of Pharmacy, University of Wisconsin\u2013Madison , Madison, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Hutson","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Translational Research Division, School of Pharmacy, University of Wisconsin\u2013Madison , Madison, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-5993","authenticated-orcid":false,"given":"Warren E","family":"Rose","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Translational Research Division, School of Pharmacy, University of Wisconsin\u2013Madison , Madison, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2024062714310154000_ofae315-B1","author":"Durata Therapeutics Inc"},{"key":"2024062714310154000_ofae315-B2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2024062714310154000_ofae315-B3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024062714310154000_ofae315-B4","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024062714310154000_ofae315-B5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024062714310154000_ofae315-B6","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2024062714310154000_ofae315-B7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2024062714310154000_ofae315-B8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2024062714310154000_ofae315-B9","doi-asserted-by":"crossref","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062714310154000_ofae315-B10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024062714310154000_ofae315-B11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsps.2020.02.007","article-title":"Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study","volume":"28","author":"Almangour","year":"2020","journal-title":"Saudi Pharm J"},{"key":"2024062714310154000_ofae315-B12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2024062714310154000_ofae315-B13","doi-asserted-by":"crossref","first-page":"ofae070","DOI":"10.1093\/ofid\/ofae070","article-title":"Dalba got back? Use of dalbavancin for the treatment of vertebral osteomyelitis","volume":"11","author":"Streifel","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2024062714310154000_ofae315-B14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","article-title":"Dalbavancin sequential therapy for gram-positive bloodstream infection: a multicenter observational study","volume":"13","author":"Rebold","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2024062714310154000_ofae315-B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024062714310154000_ofae315-B16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062714310154000_ofae315-B17","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024062714310154000_ofae315-B18","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024062714310154000_ofae315-B19","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062714310154000_ofae315-B20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024062714310154000_ofae315-B21","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against gram-positive cocci from clinical infections in the USA and Europe 2015\u201316","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024062714310154000_ofae315-B22","volume-title":"M100: performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023","edition":"33rd ed."},{"key":"2024062714310154000_ofae315-B23","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024062714310154000_ofae315-B24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.clinthera.2016.07.094","article-title":"Anti-infective dosing for obese adult patients: a focus on newer drugs to treat methicillin-resistant Staphylococcus aureus acute bacterial skin and skin structure infections","volume":"38","author":"Pai","year":"2016","journal-title":"Clin Ther"},{"key":"2024062714310154000_ofae315-B25","doi-asserted-by":"crossref","first-page":"ofad256","DOI":"10.1093\/ofid\/ofad256","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infection in patients with obesity or diabetes: a subgroup analysis of pooled phase 3 clinical trials","volume":"10","author":"Riccobene","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae315\/58123081\/ofae315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae315\/58345219\/ofae315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae315\/58345219\/ofae315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:31:03Z","timestamp":1719509463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae315\/7688760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae315","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6]]},"article-number":"ofae315"}}